BioSpace News Archive

AmerisourceBergen Corporation reported that in its fiscal year 2019 fourth quarter ended September 30, 2019, revenue increased 5.4 percent to $45.6 billion.

Phase 3 URIROX-1 Trial Achieves Primary Endpoint with Statistically Significant Reduction in Urinary Oxalate in Patients with Enteric Hyperoxaluria

Protalix BioTherapeutics, Inc. announced its third quarter 2019 financial results and provided a corporate update.

GAAP(1) operating loss was $5.3 billion and included a $5.6 billion accrual related to opioid litigation, non-GAAP operating earnings increased 6 percent to $577 million

Neovasc, Inc., a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced the appointment of Bill Little as the Company’s Chief Operating Officer, reporting directly to the CEO.

Lexicon Pharmaceuticals, Inc., reported financial results and provided a business update for the three months ended September 30, 2019.

Arch Biopartners Inc., announced that the Phase I human trial of Metablok, the Company’s lead drug candidate for treating organ damage caused by inflammation, has met the primary endpoints of safety and tolerability in the trial’s three single ascending dose cohorts of healthy volunteers.

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced its operational and financial results for the third quarter ended September 30, 2019.

Teva Pharmaceutical Industries Ltd. announced the appointment of Eli Kalif as Executive Vice President and Chief Financial Officer. Mr. Kalif will begin his employment on December 22, 2019.

Reached an agreement to be acquired by Alexion; transaction expected to close in first half of 2020